Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 486 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALS Clear all
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 21, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing

NCT04394871
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis Type 4, Inherited Neurological Disorders of RNA Processing
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
5 Years to 120 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Remote Ischemic Conditioning on Hand Use in Individuals With SCI and ALS

NCT03851302
View directory record Official record
Conditions
Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
Interventions
Active Remote Ischemic Conditioning, Sham Remote Ischemic Conditioning, Isometric hand exercise
Other
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 5:45 AM EDT
Withdrawn No phase listed Observational

Biomarkers in Neurodegenerative Diseases

NCT04055532
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD), Parkinsons Disease With Dementia (PDD), Transient Epileptic Amnesia (TEA), Temporal Lobe Epilepsy (TLE), Spinocerebellar Ataxias (SCA), HIV Associated Neurocognitive Disorder (HAND), Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS)
Interventions
Neuraceq
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 21, 2026, 5:45 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

NCT04972487
View directory record Official record
Conditions
Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
Interventions
Tofersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
U.S. locations
19
States / cities
Anchorage, Alaska • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis

NCT01124292
View directory record Official record
Conditions
Quadriplegia, Spinal Cord Injury, ALS
Interventions
Tongue Piercing, Usability assessment
Procedure · Device
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 21, 2026, 5:45 AM EDT
Terminated No phase listed Observational Results available

Lower Extremity Fixation In Neuropathic Patients Study

NCT04607044
View directory record Official record
Conditions
Neuropathy, Charcot; Disease (Etiology)
Interventions
SALVATION™ EXTERNAL FIXATION
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Trinity, Florida • West Chester, Pennsylvania • Sparta, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 21, 2026, 5:45 AM EDT
Completed No phase listed Observational Results available

DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS

NCT02675075
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

ALS Reversals - Lunasin Regimen

NCT02709330
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Lunasin Regimen, Historical control
Drug · Other
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis

NCT01119001
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
P300 Brain Computer Interface Keyboard
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 21, 2026, 5:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Olfactory Deficits in Neurologic Disease

NCT05019014
View directory record Official record
Conditions
Alzheimer Disease, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Lewy Body Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 21, 2026, 5:45 AM EDT
Recruiting No phase listed Observational

ALS/MND Natural History Study Data Repository

NCT05966038
View directory record Official record
Conditions
ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy, PBP - Progressive Bulbar Palsy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
14
States / cities
Loma Linda, California • Los Angeles, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT02460679
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
EPI-589
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
21 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 5:45 AM EDT
No Longer Available No phase listed Expanded access

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

NCT06743776
View directory record Official record
Conditions
ALS
Interventions
MN-166
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
U.S. locations
15
States / cities
Scottsdale, Arizona • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NP001, Placebo
Drug
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Early Feasibility Study of the MyoRegulator® for Treatment of ALS

NCT06165172
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MyoRegulator®
Device
Lead sponsor
PathMaker Neurosystems Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 21, 2026, 5:45 AM EDT
Approved For Marketing No phase listed Expanded access

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

NCT05286372
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 21, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

NCT05053035
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AL001, Placebo
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Phase II Study Using Thalidomide for the Treatment of ALS

NCT00140452
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Thalidomide
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 21, 2007 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 2Phase 3 Interventional

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

NCT00706147
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Arimoclomol, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 21, 2026, 5:45 AM EDT
Terminated Not applicable Interventional Results available

Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis

NCT00537446
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
noninvasive positive pressure ventilation
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants

NCT05795907
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
SAR443820, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 21, 2026, 5:45 AM EDT
Completed No phase listed Observational

Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org

NCT00302198
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALS Registry
Behavioral
Lead sponsor
Forbes Norris MDA/ALS Research Center
Other
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 21, 2026, 5:45 AM EDT